|
Safety and efficacy of a novel anti-CD20/CD19 bi-specific CAR T-cell therapy (C-CAR039) in relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL). |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Cellular Biomedicine Group |
Stock and Other Ownership Interests - Cellular Biomedicine Group |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Employment - Cellular Biomedicine Group |
Stock and Other Ownership Interests - Cellular Biomedicine Group |
|
|
Employment - Cellular Biomedicine Group |
Stock and Other Ownership Interests - Cellular Biomedicine Group |
|
|
No Relationships to Disclose |
|
|
Employment - Cellular Biomedicine Group |
Stock and Other Ownership Interests - Cellular Biomedicine Group |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |